These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35575178)

  • 1. Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets.
    Becker E; Schweda A; Ullrich KA; Voskens C; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
    Clin Transl Gastroenterol; 2022 Jun; 13(6):e00494. PubMed ID: 35575178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice.
    Ling L; Wu T; To KKW; Cheung KW; Lui KOL; Niu M; Lam KS; Wang CC; Li J; Wang H; Yuen KY; Chen Z
    AIDS; 2019 Mar; 33(4):F1-F12. PubMed ID: 30829743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
    Wittner M; Schlicker V; Libera J; Bockmann JH; Horvatits T; Seiz O; Kummer S; Manthey CF; Hüfner A; Kantowski M; Rösch T; Degen O; Huber S; Eberhard JM; Schulze Zur Wiesch J
    PLoS One; 2019; 14(7):e0220008. PubMed ID: 31356607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual homing of α4β7-expressing β1
    Becker E; Dedden M; Gall C; Wiendl M; Ekici AB; Schulz-Kuhnt A; Schweda A; Voskens C; Hegazy A; Vitali F; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
    Gut; 2022 Aug; 71(8):1551-1566. PubMed ID: 34462337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.
    Wyant T; Yang L; Fedyk E
    MAbs; 2013; 5(6):842-50. PubMed ID: 24492340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
    J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
    Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
    Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
    J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
    Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
    Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease.
    Schneider I; Allner C; Mühl L; Melde M; Lissner D; Mantzivi E; Glauben R; Vitali F; Becker E; Atreya I; Müller TM; Atreya R; Siegmund B; Neurath MF; Zundler S
    Transl Res; 2023 Mar; 253():8-15. PubMed ID: 36272713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
    Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
    Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.